Back to Screener

Healthcare

Guardian Pharmacy Services, Inc.(GRDN)

Live Price

Offline

$41.89

-1.23% today

1Y Change

+106.25%

Window

Jun 25, 2025 โ†’ Jun 22, 2026

Market Cap
$2.33B
Revenue Growth
+17.9%
EPS Growth
+144.6%
Dividend Yield
0.0%

Coverage: 248 bars ยท Jun 25, 2025 โ†’ Jun 22, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Guardian Pharmacy Services, Inc. (GRDN) is a Healthcare stock with a market cap of $2.33B and listed on NYSE. The stock last traded around $41.89 and up 106.3% across the available one-year price window (Jun 25, 2025 โ†’ Jun 22, 2026). Baseline metrics include revenue growth of +17.9%, EPS growth of +144.6%, a dividend yield of 0.0%. What stands out right now is revenue +17.9%, EPS +144.6%, free cash flow +94.1% with operating margin 6.1% and ROIC 22.3%. Valuation already assumes a fairly strong business story at P/E 47.4 and price/sales 1.6. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines GRDN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Above sector median

+17.9% vs +7.6% peer median

Operating Margin

Below sector median

+6.1% vs +19.4% peer median

P/E

Above sector median

47.4 vs 36.3 peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on May 11, 2026, but the surprise data is still limited.

The operating story is still moving forward

Revenue is running at +17.9% and EPS at +144.6%, with operating margin around 6.1%.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged -1.0% over the next 5 trading days and finished higher after 2 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2026
May 11, 2026
โ€”-2.1%+0.5%+17.3%
2026
Mar 11, 2026
+37.0%-0.7%+1.2%+21.3%
2025
Nov 10, 2025
+4.2%+5.0%-4.8%-1.9%

Benchmark Edge

GRDN vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

GRDN

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

GRDN Max Drawdown

-22.74%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for GRDN and SPY.

Calendar-year return history is still loading or unavailable.
Guardian Pharmacy Services, Inc. logo

Company Overview

Guardian Pharmacy Services, Inc.

New York Stock Exchange

Atlanta, GA, US
Visit guardianpharmacy.comCall IR404 810 0089

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

Leadership
Fred Burke
IPO Date
Apr 21, 2016
Employees
3.4k
Street Address
300 Galleria Parkway SE
Mailing
Atlanta, GA, 30339
Region
Atlanta, GA, US
Reporting Currency
USD
Investor Line
404 810 0089
Last Updated
Apr 29, 2026
CIK: 0001802255ISIN: US40145W1018CUSIP: 40145W101
Reports in USDSEC Registered

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
47.4
EV/EBITDA
22.5
Price/Sales
1.6
Price/Book
11.3

Growth

Revenue
+17.9%
EPS
+144.6%
Free Cash Flow
+94.1%

Profitability

Gross Margin
19.5%
Operating Margin
6.1%
Net Margin
3.4%
ROE
27.5%
ROIC
22.3%

Balance Sheet

Debt/Equity
0.22
Current Ratio
1.38

Earnings Reports

๐Ÿ“… Last reportedMay 11, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
May 11, 26
โ€”
Est 0.24
โ€”
โ€”
Est 331645.5B
โ€”
โ€”
Mar 11, 26
โœ“
0.37
Est 0.27
+37.0%
397616.0B
Est 390041.3B
+1.9%
โ€”
Nov 10, 25
โœ“
0.25
Est 0.24
+4.2%
377427.0B
Est 390041.3B
-3.2%
โ€”
Aug 11, 25
โœ“
0.23
Est 0.22
+4.5%
344334.0B
Est 344148.3B
+0.1%
โ€”
May 12, 25
โœ—
0.21
Est 0.22
-4.5%
329308.0B
Est 329437.0B
-0.0%
โ€”
Mar 26, 25
โœ“
0.24
Est 0.21
+14.3%
338569.0B
Est 323086.0B
+4.8%
โ€”
Nov 12, 24
โœ—
-2.00
Est 0.19
-1152.6%
314393.0B
Est 303125.3B
+3.7%
โ€”
Sep 26, 24
0.17
Est โ€”
โ€”
300037.0B
Est โ€”
โ€”
โ€”
Aug 22, 24
0.24
Est โ€”
โ€”
300037.0B
Est โ€”
โ€”
โ€”
Dec 31, 23
0.10
Est โ€”
โ€”
1046193.0B
Est โ€”
โ€”
โ€”
Sep 30, 23
-0.19
Est โ€”
โ€”
262741.0B
Est โ€”
โ€”
โ€”
Jun 30, 23
0.35
Est โ€”
โ€”
253439.0B
Est โ€”
โ€”
โ€”
Mar 31, 23
0.03
Est โ€”
โ€”
248946.0B
Est โ€”
โ€”
โ€”
Jun 30, 22
-0.10
Est โ€”
โ€”
224078.0B
Est โ€”
โ€”
โ€”
Mar 31, 22
0.30
Est โ€”
โ€”
211049.0B
Est โ€”
โ€”
โ€”
Dec 31, 21
0.07
Est โ€”
โ€”
792072.0B
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks